OncoMatch/Clinical Trials/Breast Cancer
Breast Cancer Clinical Trials
OncoMatch filters Breast Cancer trials by the molecular markers that determine eligibility — ERBB2, ESR1, PGR, BRCA1, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Breast Cancer trials
Breast cancer trials sort largely by tumor subtype, so biomarker testing starts with the markers that define which trials apply to you. Hormone receptor status (ESR1 and PR / PGR) and HER2 (ERBB2) determine the broad category: HR-positive, HER2-positive, HR-positive / HER2-positive, or triple-negative. ESR1 mutations specifically (separate from ER status) flag acquired endocrine resistance and gate trials of newer endocrine agents. Beyond subtype, trials look at BRCA1, BRCA2, and PALB2 for hereditary risk and PARP inhibitor eligibility. PIK3CA, PTEN, and ATM gate trials in the PI3K / AKT pathway. PD-L1 (CD274) drives immunotherapy trials in select settings. AR (androgen receptor) is tested for trials in AR-positive disease, particularly luminal AR-subtype tumors. TP53 and ERBB3 provide context for several combination and resistance trials.
Active trials in breast cancer split by subtype. Hormone receptor-positive trials test new endocrine combinations, post-CDK4/6 strategies, and oral SERDs for ESR1-mutated disease. HER2-positive trials are increasingly subdivided by expression level (HER2-positive standard, HER2-low, and the newer HER2-ultralow category), with antibody-drug conjugate (ADC) trials expanding into earlier lines. Triple-negative trials focus on IO combinations, ADC trials, and PARP combinations in BRCA-mutated disease. Brain metastasis trials are common in HER2-positive and TNBC settings, sometimes as dedicated cohorts within larger trials. PIK3CA-mutated trials test PI3K-alpha and AKT inhibitors in HR-positive metastatic disease.
Breast cancer trials commonly screen on a few recurring clinical features beyond subtype. Subtype confirmation: HR and HER2 status. Prior therapy lines and which classes: most trials want a specific number of prior lines and may exclude certain prior agents. Brain metastasis status and whether they're treated, stable, or asymptomatic. For HR-positive trials: prior CDK4/6 inhibitor exposure comes up in most metastatic trials (required, allowed, or excluded depending on design). For HER2-positive trials: prior anti-HER2 agents and which generation. For PARP trials: confirmed germline or somatic BRCA1, BRCA2, or PALB2 mutation. ECOG of 0 or 1 is standard. Visceral crisis is excluded by most metastatic trials.
Biomarkers tested in Breast Cancer trials
These are the molecular markers most commonly required or evaluated in Breast Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Breast Cancer trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NRG Oncology
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NRG Oncology
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group
E-Mindfulness Approaches for Living After Breast Cancer
NRG Oncology
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
How OncoMatch finds Breast Cancer trials for you
AI reads the protocol
Every Breast Cancer trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Breast Cancer and mark your biomarker results — ERBB2, ESR1, PGR — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.